prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, SPECIMENS: A. LEFT BREAST WLE NEEDLE LOCALIZATION. B. SLN #1. C. SLN#2. D. SLN #3. E. SLN #4. SPECIMEN(S): A. LEFT BREAST WLE NEEDLE LOCALIZATION. B. SLN #1. C. SLN#2. D. SLN #3. E. SLN #4. INTRAOPERATIVE CONSULTATION DIAGNOSIS: A- left breast, WLE gross examination only: 1 cm tumor located 1 cm from the closest/posterior margin. called by Dr. to Dr. it. TPB/TPC/TPD/TPE-SLN #1, 2, 3, 4: No tumor cells seen by touch prep. Part D. contains only fat tissue. called by Dr. to Dr. at. GROSS DESCRIPTION: A. LEFT BREAST WLE NEEDLE LOCALIZATION. Received fresh with accompanying radiogram is an oriented 41 g lumpectomy specimen with. localization needle. The specimen is oriented with a single suture designating anterior, double lateral,. triple superior. The specimen measures 5.8 cm from anterior to posterior, 5.2 cm from superior to. inferior, and 2.8 cm from medial to lateral. Specimen is inked as follows: inferior-orange, superior-red,. lateral-yellow, anterior-blue, medial-green, posterior-black. Specimen is serially sectioned from superior. to inferior; there is a firm well-circumscribed white-tan nodule measuring 1 cm located 1 cm from the. nearest posterior and anterior margins, 1.8 cm from the lateral margin, 3.1 cm from the medial margin,. and greater than 3 cm from the superior and inferior margins. A gross diagnosis is conveyed to O. R. A. portion of the mass is submitted for tissue procurement. Specimen is submitted entirely as follows: A1-A3: superior margin perpendicular sections. A4: slice 2, medial. A5: slice 2, mid. A6: slice 2, lateral. A7: slice 3, medial. A8: slice 3, mid. A9: slice 3, lateral. A10: slice 4, medial. A11: slice 4, mid {lesion}. A12: slice 4, lateral. A13: slice 5, medial. A14-A15: slice 5, mid {lesion}. A16: slice 5, lateral. A17: slice 6, medial. A18: slice 6, mid-anterior {lesion}. A19: slice 6, mid-posterior {lesion}. A20: slice 6, anterior-lateral. A21: slice 6: posterior-lateral. A22: slice 7, medial. A23: slice 7, mid. A24: slice 7, lateral. A25-A26: inferior margin, perpendicular sections. B. SLN#1. Received fresh is a lymph node measuring 0.7 cm in diameter. One touch prep is performed. The. specimen is submitted entirely in cassette B1. C. SLN #2. Received fresh is one lymph node measuring 0.4 cm in diameter. A touch prep is performed. The. specimen is submitted entirely in cassette C1. D. SLN #3. Received fresh is a piece of fatty tissue measuring 0.5 x 0.3 x 0.3 cm. A touch prep is performed and. the specimen is submitted entirely in cassette D1. E. SLN #4. Received fresh is a lymph node measuring 0.4 cm in diameter. A touch prep is performed the specimen. is submitted entirely in cassette E1. DIAGNOSIS: A. BREAST, LEFT, WIDE LOCAL EXCISION: - INVASIVE, DUCTAL CARCINOMA, SBR GRADE 1, MEASURING 1.2-CM. - INVASIVE TUMOR PRESENT WITHIN 0.15-CM FROM MEDIAL SURGICAL. RESECTION MARGIN. - LOW TO INTERMEDIATE NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU,. CRIBRIFORM TYPE. - DUCTAL HYPERPLASIA INVOLVING INTRADUCTAL PAPILLOMA. - SEE SYNOPTIC REPORTS SEE NOTE. B. LYMPH NODE, SENTINEL #1, BIOPSY: -METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.5-MM (MICROMETASTASES) WITH NO EXTRANODAL. EXTENSION, SEE NOTE. C. LYMPH NODE, SENTINEL #2, BIOPSY: -METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.6-MM (MICROMETASTASES) WITH NO EXTRANODAL. EXTENSION, SEE NOTE. D. LYMPH NODE, SENTINEL #3, BIOPSY: - ONE LYMPH NODE, NEGATIVE FOR METASTASES (0/1). E. LYMPH NODE, SENTINEL #4, BIOPSY: -METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 2.0-MM (MICROMETASTASES) WITH NO EXTRANODAL. EXTENSION, SEE NOTE. NOTE: Two foci of intraductal papilloma with usual ductal hyperplasia are identified, one adjacent to the. invasive tumor and one at the posterior surgical resection margin. p63 and calponin mark the. myoepithelial cell layer in the papilloma. Dr. concurs on this interpretation. Micrometastases are identified in sentinel lymph nodes#1, #2 (AE 1/3 positive) and #4. The largest. tumor metastasis measures 2-mm. The touch preparations were reviewed, no tumor cells identified. Therefore, this discrepancy is due to sampling error. SYNOPTIC REPORT - BREAST. Specimen Type: Excision. Needle Localization: Yes - For mass. Laterality: Left. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 1.2cm. Tumor Site: Upper inner quadrant. Margins: Negative. Distance from closest margin: 0.15cm. medial. Tubular Score: 1. Nuclear Grade: 2. Mitotic Score: 1. Modified Scarff Bloom Richardson Grade: 1. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node only. Lymph node status: Positive 3/4. Micrometastases: DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 5%. DCIS Type: Cribriform. DCIS Location: Associated with invasive tumor. Nuclear grade: Intermediate. Necrosis: Absent. Location of CA++: DCIS. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Negative. Pathological staging (pTN): pT 1c N mi. SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Surgical Excision. Block Number: A18. ER: Positive Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Positive Allred Score: 8 = Proportion Score 5 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2. METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by Dako. blowing the manufacturer S instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Surgical Excision. Block Number: A18. Interpretation: NEGATIVE. Intensity: 1+. % Tumor Staining: 10%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved Dako HercepTest (TM) test kit (. C. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate,. well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the. joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in breast Cancer Task Force. The Pathology. Department takes full responsibility for this test's performance. CLINICAL HISTORY: Core biopsy proven cancer upper inner quadrant left breast. PRE-OPERATIVE DIAGNOSIS: Left breast cancer. ADDENDUM: ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 7. CLINICAL EXPERIENCE: Patients with a recurrence score of: 7 in the clinical validation study had. an average rate of Distant Recurrence at 10 years of 6%. ER Score: 11.1 Positive. PR Score: 8.9 Positive. Her2 Score: 9.9 Negative. Interpretation: ER. Negative < 6.5. Positive >= 6.5. PR. Negative < 5.5. Positive >= 5.5. Her2 Negative <10.7 Positive >=11.5 Equivocal = 10.7 - 11.4. See separate. report for further information. Microscopic/Diagnostic Dictation: Pathologist. Final Review: Pathologist,. Final: Pathologist,. Addendum: Pathologist,. Addendum Final: Pathologist.

expanded version (tokens=2841) : 
 This report contains information about the biopsy of a left breast cancer and related lymph nodes. The following information was extracted from the report:

Histological classification:
- Invasive ductal carcinoma, NOS
- Ductal carcinoma in situ, cribriform type
- Low to intermediate nuclear grade

Subtype:
- Luminal A

Necrosis:
- Absent

Tumor infiltrating lymphocytes:
- None mentioned

Histological grade:
- SBR grade 1

Nuclear grade:
- 2

Lymphovascular invasion:
- None identified

Calcification:
- DCIS associated with invasive tumor, location of CA++: DCIS.

Receptor status:
- ER: Positive
- PR: Positive
- HER2: Negative

IHC and other ancillary tests:
- Sent for Oncotype DX Breast Cancer assay, recurrence score: 7, ER Score: 11.1 Positive, PR Score: 8.9 Positive, Her2 Score: 9.9 Negative
- p63 and calponin mark the myoepithelial cell layer in the papilloma

Additionally, the report contains information about the size and location of the tumor, involvement of lymph nodes, margins, and any other findings in relation to the biopsy. The lymph nodes were checked using touch preparation, and micrometastases were identified in sentinel lymph nodes. Intraductal papilloma with usual ductal hyperplasia was identified,

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=3014) : 
 Left breast luminal A subtype invasive ductal carcinoma with ductal carcinoma in situ (cribriform type), low to intermediate nuclear grade, ER/PR positive, HER2 negative. The tumor is 1.2 cm and located in upper inner quadrant with negative margins and no lymphovascular invasion. Micrometastases were found in sentinel lymph nodes. Oncotype DX recurrence score is 7 with a 6% distant recurrence rate in ten years for patients with this score. Intraductal papilloma with usual ductal hyperplasia seen near the invasive tumor and at posterior surgical resection margin.

